Sale!

OTOA Gene Deafness Autosomal Recessive Type 22 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The OTOA Gene Deafness Autosomal Recessive Type 22 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in the OTOA gene, which are associated with autosomal recessive deafness type 22 (DFNB22). This condition is characterized by non-syndromic sensorineural hearing loss, meaning it affects the inner ear or nerve pathways to the brain without other associated medical issues. The test is crucial for early diagnosis and management of the condition, particularly in families with a history of hearing loss. By analyzing a person’s DNA, the test can confirm the presence of specific genetic alterations in the OTOA gene that lead to this form of deafness. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify these genetic markers. Conducted in the state-of-the-art facilities of DNA Labs UAE, this genetic test is a vital tool for individuals seeking to understand their genetic health, especially in the context of family planning or early intervention strategies for affected individuals.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

OTOA Gene Deafness Autosomal Recessive Type 22 Genetic Test

At DNA Labs UAE, we offer the OTOA Gene Deafness Autosomal Recessive Type 22 Genetic Test at a cost of AED 4400.0. This test is used to diagnose and identify the specific type of genetic deafness caused by mutations in the OTOA gene.

Test Components

  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Ear Nose Throat Disorders
  • Doctor: ENT Doctor
  • Test Department: Genetics

Pre Test Information

Prior to undergoing the IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test, it is important to provide the clinical history of the patient. A Genetic Counselling session will be conducted to draw a pedigree chart of family members affected with the IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS8.

Test Details

OTOA gene deafness, autosomal recessive type 22 is a specific type of genetic deafness caused by mutations in the OTOA gene. This gene is responsible for producing a protein called otoancorin, which plays a crucial role in the development and function of hair cells in the inner ear. Hair cells are responsible for converting sound vibrations into electrical signals that the brain can interpret. Mutations in the OTOA gene can disrupt the production or function of otoancorin, leading to the loss of hair cells and resulting in hearing loss.

This type of deafness is inherited in an autosomal recessive manner, which means that both copies of the OTOA gene must have mutations for an individual to be affected. NGS (Next-Generation Sequencing) genetic testing is used to analyze multiple genes at once using advanced sequencing technologies. In the case of OTOA gene deafness, autosomal recessive type 22, NGS genetic testing can identify mutations in the OTOA gene associated with this specific type of deafness.

NGS genetic testing for OTOA gene deafness, autosomal recessive type 22 can help diagnose individuals with this condition and provide information about the inheritance pattern. It can also be used for carrier testing to determine if an individual carries a mutation in the OTOA gene and has a risk of passing it on to their children. This test provides important information for individuals and families affected by OTOA gene deafness, autosomal recessive type 22, assisting with diagnosis, prognosis, and family planning decisions.

Test Name OTOA Gene Deafness autosomal recessive type 22 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Ear Nose Throat Disorders
Doctor ENT Doctor
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS8
Test Details

OTOA gene deafness, autosomal recessive type 22 refers to a specific type of genetic deafness that is caused by mutations in the OTOA gene. This gene provides instructions for making a protein called otoancorin, which is found in the inner ear and plays a crucial role in the development and function of hair cells. Hair cells are responsible for converting sound vibrations into electrical signals that can be interpreted by the brain.

Mutations in the OTOA gene can disrupt the production or function of otoancorin, leading to the loss of hair cells and resulting in hearing loss. This type of deafness is inherited in an autosomal recessive manner, which means that both copies of the OTOA gene must have mutations for an individual to be affected.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that uses advanced sequencing technologies to rapidly and accurately analyze multiple genes at once. In the case of OTOA gene deafness, autosomal recessive type 22, NGS genetic testing can identify mutations in the OTOA gene that are associated with this specific type of deafness.

NGS genetic testing can help diagnose individuals with OTOA gene deafness, autosomal recessive type 22 and provide information about the inheritance pattern of the condition. It can also be used for carrier testing to determine if an individual carries a mutation in the OTOA gene and has a risk of passing it on to their children.

Overall, NGS genetic testing for OTOA gene deafness, autosomal recessive type 22 can provide important information for individuals and families affected by this condition, helping with diagnosis, prognosis, and family planning decisions.